Citigroup’s PRA Health Sciences, Inc. PRAH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-1,294,271
| Closed | -$214M | – | 6568 |
|
|
2021
Q2 | $214M | Buy |
1,294,271
+282,767
| +28% | +$47.2M | 0.13% | 142 |
|
|
2021
Q1 | $155M | Buy |
1,011,504
+992,093
| +5,111% | +$135M | 0.1% | 185 |
|
|
2020
Q4 | $2.44M | Buy |
19,411
+10,957
| +130% | +$1.23M | ﹤0.01% | 2672 |
|
|
2020
Q3 | $858K | Sell |
8,454
-10,911
| -56% | -$1.11M | ﹤0.01% | 3413 |
|
|
2020
Q2 | $1.88M | Buy |
19,365
+10,692
| +123% | +$995K | ﹤0.01% | 2874 |
|
|
2020
Q1 | $720K | Sell |
8,673
-1,153
| -12% | -$112K | ﹤0.01% | 3520 |
|
|
2019
Q4 | $1.09M | Buy |
9,826
+4,523
| +85% | +$465K | ﹤0.01% | 3655 |
|
|
2019
Q3 | $525K | Buy |
5,303
+3,943
| +290% | +$392K | ﹤0.01% | 4295 |
|
|
2019
Q2 | $135K | Sell |
1,360
-15,960
| -92% | -$1.52M | ﹤0.01% | 5602 |
|
|
2019
Q1 | $1.91M | Buy |
17,320
+14,325
| +478% | +$1.5M | ﹤0.01% | 2698 |
|
|
2018
Q4 | $275K | Sell |
2,995
-5,687
| -66% | -$575K | ﹤0.01% | 4711 |
|
|
2018
Q3 | $956K | Buy |
8,682
+5,514
| +174% | +$574K | ﹤0.01% | 3555 |
|
|
2018
Q2 | $295K | Sell |
3,168
-10,230
| -76% | -$881K | ﹤0.01% | 4646 |
|
|
2018
Q1 | $1.11M | Buy |
13,398
+12,935
| +2,794% | +$1.15M | ﹤0.01% | 3144 |
|
|
2017
Q4 | $42K | Sell |
463
-51,619
| -99% | -$4.29M | ﹤0.01% | 6304 |
|
|
2017
Q3 | $3.97M | Buy |
52,082
+34,750
| +200% | +$2.63M | ﹤0.01% | 1978 |
|
|
2017
Q2 | $1.3M | Buy |
17,332
+11,028
| +175% | +$764K | ﹤0.01% | 3044 |
|
|
2017
Q1 | $412K | Sell |
6,304
-25,259
| -80% | -$1.49M | ﹤0.01% | 4037 |
|
|
2016
Q4 | $1.74M | Buy |
31,563
+16,500
| +110% | +$906K | ﹤0.01% | 3107 |
|
|
2016
Q3 | $851K | Buy |
15,063
+3,811
| +34% | +$187K | ﹤0.01% | 3398 |
|
|
2016
Q2 | $470K | Sell |
11,252
-2,942
| -21% | -$136K | ﹤0.01% | 3730 |
|
|
2016
Q1 | $607K | Buy |
14,194
+14,159
| +40,454% | +$598K | ﹤0.01% | 3918 |
|
|
2015
Q4 | $2K | Buy |
35
+15
| +75% | +$630 | ﹤0.01% | 7308 |
|
|
2015
Q3 | $1K | Sell |
20
-44,551
| -100% | -$1.78M | ﹤0.01% | 7259 |
|
|
2015
Q2 | $1.62M | Buy |
44,571
+23,979
| +116% | +$758K | ﹤0.01% | 2741 |
|
|
2015
Q1 | $594K | Buy |
20,592
+17,244
| +515% | +$481K | ﹤0.01% | 3578 |
|
|
2014
Q4 | $81K | Buy |
+3,348
| New | +$75.5K | ﹤0.01% | 5389 |
|
Other funds holding PRAH
Citigroup's PRAH Position: Q3 2021 in Review
Citigroup sold out of PRA Health Sciences, Inc. (PRAH) in Q3 2021, closing a stake of 1,294,271 shares — an estimated $214M sold.
Citigroup first reported a position in PRAH in Q4 2014 and held it in 27 quarters. The position peaked at $214M in Q2 2021. 1 fund tracked by Wall St. Rank holds PRAH as of Q3 2021.
- Citigroup reported no remaining PRA Health Sciences, Inc. position as of Q3 2021 after selling out during the quarter.
- Citigroup sold 1,294,271 PRA Health Sciences, Inc. shares in Q3 2021, an estimated $214M.
- Citigroup first reported a position in PRA Health Sciences, Inc. in Q4 2014 and held it in 27 quarters.
- Citigroup's PRA Health Sciences, Inc. position peaked at $214M in Q2 2021.
- 1 fund tracked by Wall St. Rank held PRA Health Sciences, Inc. as of Q3 2021.
Based on Citigroup's 13F filing for Q3 2021, filed 10 Nov 2021.